1. A pharmaceutical dosage form showing a tensile strength of at least 500 N and containing a pharmacologically active component (A)； an inorganic salt (B), where the content of inorganic salt (B) is from 5 to 70 wt.%, Based on the total weight of the dosage form； a polyalkylene oxide (C) having a weight average molecular weight of at least 200,000 g / mol, where the content of the polyalkylene oxide (C) is at least 30 wt.% based on the total weight of the dosage form； where pharmacologically active component (A) is embedded in the matrix controlled-release cs containing inorganic salt (B) and polyalkylene oxide (C), and in vitro, the release profile of the pharmacologically active component (A) from the matrix includes at least a time interval during which the release corresponds to zero kinetics order 2. The pharmaceutical dosage form of claim 1, wherein the time interval during which the release corresponds to zero order kinetics is at least 20% of the total release time required to release 95% by weight of the pharmacologically active component (A) that is initially present. . A pharmaceutical dosage form according to claim 1 or 2, wherein the release profile corresponds to zero order kinetics in the range from pH 1 to pH 74. The pharmaceutical dosage form according to claim 1 or 2, which is obtained by hot melt extrusion. The pharmaceutical dosage form according to claim 1 or 2, which is a tablet. The pharmaceutical dosage form according to claim 1 or 2, wherein the pharmacologically active component (A) is1. Фармацевтическая лекарственная форма, проявляющая прочность не разрыв по меньшей мере 500 Н и содержащая- фармакологически активный компонент (А)；- неорганическую соль (В), где содержание неорганической соли (В) составляет от 5 до 70 мас.%, исходя из общей массы лекарственной формы；- полиалкилен оксид (С), имеющий средневесовую молекулярную массу по меньшей мере 200,000 г/моль, где содержание полиалкилен оксида (С) составляет по меньшей мере 30 мас.%, исхо
